L-055-2022
Agreement ID
L-055-2022
Lead IC
NCI
Exclusivity
Exclusive
External Party
Neogene Therapeutics, Inc.
Fiscal Year
2022
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-4010 Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations
TAB-4212 T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy
TAB-4297 T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy
TAB-4212 T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy
TAB-4297 T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy